Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,346.00
Bid: 12,376.00
Ask: 12,380.00
Change: 156.00 (1.28%)
Spread: 4.00 (0.032%)
Open: 12,304.00
High: 12,380.00
Low: 12,088.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-S.Africa targets COVID-19 vaccines next month but deals not yet signed

Sun, 03rd Jan 2021 17:52

* S.Africa battling COVID-19 resurgence

* Experts criticise govt's vaccine strategy

* Ministry still in talks with pharma companies over deals

* Vaccines from COVAX scheme only expected in Q2
(Adds detail on govt rollout plan)

By Alexander Winning

JOHANNESBURG, Jan 3 (Reuters) - South Africa aims to get
COVID-19 vaccines by next month but is still in talks with
pharmaceutical companies and no deals have been signed yet,
Health Minister Zweli Mkhize said on Sunday, amid growing
criticism of the government's response.

The country is battling a resurgence in coronavirus
infections driven partly by a new variant called 501.V2. It has
recorded more than 1 million infections, the most on the African
continent, and more than 29,000 deaths.

In an opinion piece published in major local news outlets on
Saturday, a group of prominent health experts criticised the
government for moving too slowly to procure sufficient vaccines.

Africa's most industrialised nation is participating in the
COVAX vaccine distribution initiative co-led by the World Health
Organization but the scheme could only cover 10% of its
population of roughly 60 million people and the first doses may
only arrive in the second quarter of the year.

That has caused anxiety among some scientists and academics,
who have urged the government to reach agreements with
pharmaceutical companies quickly given that other countries have
already started vaccinating.

Mkhize said at a news conference that officials were doing
everything possible to obtain vaccines before the COVAX doses
become available.

"We are targeting February, although all of that will depend
very much on the success of the current bilateral negotiations,"
he said.

Mkhize said the ultimate aim was to vaccinate a minimum of
67% of the population to reach herd immunity.

He said the approach would be to target frontline healthcare
workers in the first phase of vaccination, followed by a second
phase comprising essential workers, people in congregate
settings, people over the age of 60 and those aged over 18 with
co-morbidities. A third phase of the rollout would target other
people over the age of 18.

The government has had discussions with vaccine
manufacturers including Pfizer, Moderna,
AstraZeneca and Johnson & Johnson, as well as
with ones in Russia and China, a health ministry presentation
showed.

The presentation said negotiations had progressed well and
the government was fairly confident of having supply in the
first quarter.

Mkhize said officials were considering three mechanisms to
fund vaccine procurement: government financing, medical aids and
a private sector contribution.

New daily cases hit a record 18,000 several days ago but
have dipped slightly since.
(Reporting by Alexander Winning, Editing by Timothy Heritage
and Alexandra Hudson)

More News
Today 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
Today 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.